ARCON: Experience in 215 patients with advanced head-and-neck cancer

International Journal of Radiation Oncology Biology Physics

Volumn 52, Issue 3, 2002, Pages 769-778

  Kaanders, Johannes H A M ^a   Pop, Lucas A M ^a   Marres, Henri A M ^a   Bruaset, Ingolv ^a   Van Den Hoogen, Franciscus J A ^a   Merkx, Matthijs A W ^a   Van Der Kogel, Albert J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Carbogen; Fractionation; Head and neck cancer; Nicotinamide; Radiotherapy

Indexed keywords

BIOLOGICAL MATERIALS PRESERVATION; CARCINOGENS; IRRADIATION; TUMORS;

CARBOGEN BREATHING;

RADIOTHERAPY;

ANTIEMETIC AGENT; CARBOGEN; CISPLATIN; NICOTINAMIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CONTROL; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MOUTH CARCINOMA; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; ORGAN PRESERVATION; OROPHARYNX CARCINOMA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE;

ADULT; AGED; AGED, 80 AND OVER; ANOXIA; CARBON DIOXIDE; DOSE FRACTIONATION; FEASIBILITY STUDIES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NIACINAMIDE; OXYGEN; RADIATION INJURIES; RADIATION-SENSITIZING AGENTS;

EID: 0036498885     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)02678-5     Document Type: Article

References (46)

1. Overall time factor in postoperative radiation: Results of a prospective randomized trial
2. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer
3. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: Results of the EORTC 22851 randomized trial
4. Conventional radiotherapy as primary treatment of squamous cell carcinoma of the head and neck: A randomized multicenter study of 5 versus 6 fractions per week - Report from the DAHANCA 7 trial
5. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003
6. Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer - Report on 3-year tumour control and normal tissue toxicity
7. Professional guideline on larynx carcinoma
8. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome
9. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy
10. Radiotherapy and hyperbaric oxygen in head and neck cancer
11. Late results of a trial of hyperbaric oxygen and radiotherapy in head and neck cancer: A rationale for hypoxic cell sensitizers?
12. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma: Results of the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85
13. Results of a European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas
14. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas
15. The histological structure of some human lung cancers and the possible implications for radiotherapy
16. Evidence for acute hypoxic cells in mouse tumours and a possible mechanism of reoxygenation
17. The effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumour
18. Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumour cells
19. Changes in the oxygenation of head and neck tumors during carbogen breathing
20. Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: Effects of carbogen and nicotinamide
21. Radiosensitization with normobaric oxygen and carbogen
22. Carbogen and nicotinamide as radiosensitizers in a murine mammary carcinoma using conventional and accelerated radiotherapy
23. Influence of combined use of nicotinamide and carbogen on rat spinal cord radiation tolerance
24. A convenient and reliable method for carbogen breathing in man
25. Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations
26. Radiotherapy with carbogen breathing and nicotinamide in head and neck cancer: Feasibility and toxicity
27. Administration of nicotinamide during a five to seven week course of radiotherapy: Pharmacokinetics, tolerance, and compliance
28. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)
29. Nonparametric estimation from incomplete observations
30. Effect of carbogen breathing on the physiological profile of human glioma xenografts
31. 2, microcirculatory function and radiosensitivity
32. Optimising the administration of nicotinamide in patients that experience toxicity: In vivo studies with or without carbogen
33. The effect of nicotinamide on spontaneous and induced activity in smooth and skeletal muscle
34. Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: A feasibility study
35. Accelerated fractionation radiotherapy for laryngeal cancer, acute and late toxicity
36. Altered fractionation: Limited by mucosal reactions?
37. A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated x-ray treatments
38. Relative clinical influence of tumor dose versus dose per fraction on the local control and late normal-tissue morbidity after larynx radiotherapy
39. Hyperfractionated radiation in the treatment of squamous cell carcinomas of the head and neck: A comparison of two fractionation schedules
40. Radiotherapy for squamous cell carcinoma of the supraglottic larynx: An alternative to surgery
41. Results of accelerated radiotherapy for supraglottic carcinoma: A Massachusetts General Hospital and Massachusetts Eye and Ear Infirmary experience
42. Accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer (EORTC)
43. Carbogen breathing during radiation therapy: The Radiation Therapy Oncology Group study
44. 2) on the in vivo radiation response of a murine sarcoma